Compare MGIH & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | SCNX |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 16.2M |
| IPO Year | 2022 | 2019 |
| Metric | MGIH | SCNX |
|---|---|---|
| Price | $1.22 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 38.5K |
| Earning Date | 11-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $743.36 |
| Revenue Next Year | N/A | $325.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $1.11 | $2.64 |
| 52 Week High | $1.98 | $106.25 |
| Indicator | MGIH | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 46.81 |
| Support Level | N/A | $2.64 |
| Resistance Level | $1.56 | $3.68 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.00 | 0.21 |
| Stochastic Oscillator | 7.94 | 41.83 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.